Oramed Pharmaceuticals Inc. cash flow statement

In fiscal 2025, Oramed Pharmaceuticals Inc.'s operations generated −$9.1m of cash; it spent $9,000 on capital projects, leaving free cash flow of −$9.2m. It returned $4.7m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Oramed Pharmaceuticals Inc.: cash flow statement, annual
Fiscal year	2016Aug 2016	2017Aug 2017	2018Aug 2018	2019Aug 2019	2020Aug 2020	2021Aug 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025
Cash from operations	5	−6	−15	−13	−12	−21	−28	−10	−9
Depreciation and amortisation	0	0	0	0	0	0	0	0	0
Stock-based pay	1	2	2	1	0	3	12	4	6
Capital spending	0	0	0	0	0	0	0	0	0
Free cash flow	5	−6	−15	−13	−13	−22	−28	−11	−9
Free cash flow after stock pay	4	−7	−16	−14	−13	−24	−40	−15	−15
Share buybacks	—	—	—	—	—	—	—	—	5
Shares issued	11	0	22	—	—	11	12	2	—

US$ thousands unless shown otherwise. Fiscal quarters.

Oramed Pharmaceuticals Inc.: cash flow statement, quarterly
Quarter	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025
Cash from operations	−5,549	−2,634	−694	−1,418	−3,519	−3,535	−1,625	−466
Depreciation and amortisation	37	52	54	53	30	30	31	30
Stock-based pay	173	1,820	852	1,367	2,189	800	719	2,284
Capital spending	199	20	32	3	3	4	0	2
Free cash flow	−5,748	−2,654	−726	−1,421	−3,522	−3,539	−1,625	−468
Free cash flow after stock pay	−5,921	−4,474	−1,578	−2,788	−5,711	−4,339	−2,344	−2,752
Shares issued	2,430	0	−2	0	—	—	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KRSA vs ORMP MCRB vs ORMP CLGN vs ORMP

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Oramed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Oramed Pharmaceuticals Inc.